Weekly News Round-Up – 3/4/20

With the coronavirus showing no sign of letting up for the next few months at least, we won’t either, bringing you the most up-to-date news on efforts to combat Covid-19 from around the world. This week: Gilead begins remdesivir trials...

5 days ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 3/4/20

With the coronavirus showing no sign of letting up for the next few months at least, we won’t either, bringing you the most up-to-date news on efforts to combat Covid-19 from around the world. This week: Gilead begins remdesivir trials...

5 days ago

Weekly News Round-up – 27/3/20

It’s that time again! We’ve got all the news you wanted this week, as long as you wanted to read about nothing except COVID-19, constantly. But to cheer things up, we’ve left out the story that we’re heading towards a...

2 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 27/3/20

It’s that time again! We’ve got all the news you wanted this week, as long as you wanted to read about nothing except COVID-19, constantly. But to cheer things up, we’ve left out the story that we’re heading towards a...

2 weeks ago

How Close are We to a COVID-19 Treatment?

Despite the warnings of SARS, MERS, swine and bird flu, the coronavirus COVID-19 took the entire world by surprise. Governments, health workers and pharmaceutical executives were unprepared for the rapid spread of the pandemic across the globe. Now they are...

2 weeks ago
R&D,Clinical Development,Clinical Operations,News

How Close are We to a COVID-19 Treatment?

Despite the warnings of SARS, MERS, swine and bird flu, the coronavirus COVID-19 took the entire world by surprise. Governments, health workers and pharmaceutical executives were unprepared for the rapid spread of the pandemic across the globe. Now they are...

2 weeks ago

Weekly News Round-up – 20/3/20

For those of you who’ve lost track of the days in this WFH nightmare, it’s Friday again! Seeing as any pretence of not talking about coronavirus is entirely gone, welcome to: The Round-up Coronavirus Special (Part 1 of 12) UK’S...

3 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 20/3/20

For those of you who’ve lost track of the days in this WFH nightmare, it’s Friday again! Seeing as any pretence of not talking about coronavirus is entirely gone, welcome to: The Round-up Coronavirus Special (Part 1 of 12) UK’S...

3 weeks ago

Weekly News Round-Up – 6/3/20

Pharma weekly news A bit of a break from the big C-word this week, with news on three major mergers that have, like buses, all turned up at once: the Abbvie/Allergan merger has been cleared by the EU, with a...

1 month ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-Up – 6/3/20

Pharma weekly news A bit of a break from the big C-word this week, with news on three major mergers that have, like buses, all turned up at once: the Abbvie/Allergan merger has been cleared by the EU, with a...

1 month ago

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

1 month ago
Oncology,R&D,Bioinformatics,Biology,News

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

1 month ago

Weekly News Round-up – 28/2/20

Covid-19 continues to dominate the news, with pharma companies racing to find the cure. Moderna and Gilead look currently set to lead, with vaccines from both now entering human trials. In other news, Novartis' Beovu, which appeared in last week's...

1 month ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 28/2/20

Covid-19 continues to dominate the news, with pharma companies racing to find the cure. Moderna and Gilead look currently set to lead, with vaccines from both now entering human trials. In other news, Novartis' Beovu, which appeared in last week's...

1 month ago

Weekly News Round-up – 21/2/20

Fascinating news this week as scientists at MIT found the first strong antibiotics devised entirely by machine learning algorithm. The resulting medicines have so far proven highly effective against ‘critical’ pathogens. The scientists are now intending to search for more...

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 21/2/20

Fascinating news this week as scientists at MIT found the first strong antibiotics devised entirely by machine learning algorithm. The resulting medicines have so far proven highly effective against ‘critical’ pathogens. The scientists are now intending to search for more...

2 months ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 months ago
Oncology,R&D,Biology,News

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 months ago

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

2 months ago
R&D,Bioprocess,Weekly Roundups

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

2 months ago